Allovir Reports Costs from Exit/Disposal Activities on Jan 1
Ticker: KLRS · Form: 8-K · Filed: Jan 4, 2024 · CIK: 1754068
| Field | Detail |
|---|---|
| Company | Allovir, Inc. (KLRS) |
| Form Type | 8-K |
| Filed Date | Jan 4, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $13 million |
| Sentiment | mixed |
Complexity: simple
Sentiment: mixed
Topics: restructuring, operational-change, cost-management
TL;DR
**Allovir is incurring costs from winding down some operations, watch for financial impact.**
AI Summary
Allovir, Inc. filed an 8-K on January 4, 2024, reporting an event that occurred on January 1, 2024, related to "Cost Associated with Exit or Disposal Activities." This filing indicates the company is undergoing some form of restructuring or winding down certain operations, which could lead to one-time expenses. For investors, this matters because such activities often signal a strategic shift, potential cost savings in the long run, or, conversely, a reduction in scope that could impact future growth prospects.
Why It Matters
This filing signals Allovir is incurring costs related to exiting or disposing of certain activities, which could impact its financial performance and strategic direction.
Risk Assessment
Risk Level: medium — While the specific costs aren't disclosed, 'exit or disposal activities' can involve significant one-time expenses and may signal underlying operational challenges or strategic shifts.
Analyst Insight
A smart investor would monitor Allovir's upcoming financial reports for specific details on the nature and magnitude of these 'exit or disposal activities' and their financial impact, as well as any strategic rationale provided by management.
Key Players & Entities
- Allovir, Inc. (company) — the registrant filing the 8-K
- January 1, 2024 (date) — date of the earliest event reported
- January 4, 2024 (date) — date the 8-K was filed
- 001-39409 (other) — Commission File Number for Allovir, Inc.
- ALVR (other) — Trade Symbol for Allovir, Inc. Common Stock
- Nasdaq Global Select Market (other) — exchange where Allovir's stock is registered
Forward-Looking Statements
- Allovir will provide more details on the nature and financial impact of these exit or disposal activities in its next quarterly or annual report. (Allovir, Inc.) — high confidence, target: Q1 2024 Earnings Report
- The reported costs will lead to a one-time charge against earnings in the upcoming financial statements. (Allovir, Inc.) — medium confidence, target: Q1 2024 Earnings Report
FAQ
What specific event did Allovir, Inc. report in this 8-K filing?
Allovir, Inc. reported an event related to "Cost Associated with Exit or Disposal Activities" as of January 1, 2024.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 1, 2024.
What is the ticker symbol for Allovir, Inc. common stock?
The trade symbol for Allovir, Inc. common stock is ALVR.
On which exchange is Allovir, Inc.'s common stock registered?
Allovir, Inc.'s common stock is registered on the Nasdaq Global Select Market.
What is the business address of Allovir, Inc. as stated in the filing?
The business address of Allovir, Inc. is 1100 Winter Street, Waltham, Massachusetts 02451.
Filing Stats: 533 words · 2 min read · ~2 pages · Grade level 12.5 · Accepted 2024-01-04 17:21:42
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share ALVR Nasdaq Glo
- $13 million — restructuring charges of approximately $13 million in connection with one-time employee te
Filing Documents
- d35101d8k.htm (8-K) — 22KB
- 0001193125-24-002563.txt ( ) — 141KB
- alvr-20240101.xsd (EX-101.SCH) — 3KB
- alvr-20240101_lab.xml (EX-101.LAB) — 18KB
- alvr-20240101_pre.xml (EX-101.PRE) — 11KB
- d35101d8k_htm.xml (XML) — 3KB
05
Item 2.05 Costs Associated with Exit or Disposal Activities. On January 1, 2024, the board of directors of AlloVir, Inc. ("AlloVir") approved a reduction its workforce by approximately 95% of AlloVir's current employee base in order to reduce costs and preserve capital in light of AlloVir's announcement on December 22, 2023 that it is discontinuing its three global Phase 3 posoleucel studies. This workforce reduction will take place primarily during the first quarter of 2024 and expects to be substantially completed by April 15, 2024. As a result of these actions, AlloVir expects to incur personnel-related restructuring charges of approximately $13 million in connection with one-time employee termination cash expenditures, including severance and other benefits, which are expected to be substantially incurred in the first quarter of 2024. AlloVir may also incur other charges or cash expenditures not currently contemplated due to events that may occur as a result of, or associated with, the workforce reduction or retention efforts. These estimates of the costs that AlloVir expects to incur, and the timing thereof, are subject to a number of assumptions and actual results may differ. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AlloVir, Inc. Date: January 4, 2024 By: /s/ Edward Miller Name: Edward Miller Title: General Counsel